Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alset Inc. stock logo
AEI
Alset
$0.57
-3.4%
$0.78
$0.57
$2.08
$5.45M0.7347,838 shs23,050 shs
AWGI
Catapult Solutions
$0.06
-26.7%
$0.31
$0.00
$0.02
N/AN/A46.63 million shs36,510 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.18
-2.5%
$1.34
$1.09
$3.55
$88.39M0.88326,052 shs189,428 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alset Inc. stock logo
AEI
Alset
-3.36%-7.73%-17.49%-51.68%-57.45%
AWGI
Catapult Solutions
-21.43%-26.67%-39.99%-72.31%-76.09%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-2.48%+4.42%-3.28%-20.54%-52.23%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alset Inc. stock logo
AEI
Alset
N/AN/AN/AN/AN/AN/AN/AN/A
AWGI
Catapult Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.5601 of 5 stars
3.50.00.00.00.60.03.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alset Inc. stock logo
AEI
Alset
N/AN/AN/AN/A
AWGI
Catapult Solutions
N/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$10.00747.46% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alset Inc. stock logo
AEI
Alset
$22.09M0.24N/AN/A$10.48 per share0.05
AWGI
Catapult Solutions
N/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$65.49M1.32$0.13 per share8.87$0.47 per share2.51

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alset Inc. stock logo
AEI
Alset
-$58.95M-$6.48N/AN/A-266.86%-45.78%-38.81%5/20/2024 (Estimated)
AWGI
Catapult Solutions
N/A-$0.04N/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.0523.601.46N/A12.69%29.73%10.17%5/2/2024 (Estimated)

Latest PLX, TOX, AEI, 1AG, and AWGI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Alset Inc. stock logo
AEI
Alset
N/A-$3.66-$3.66-$3.66N/A$1.02 million
3/14/2024Q4 2023
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-$0.03-$0.07-$0.04-$0.07$8.15 million$10.49 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alset Inc. stock logo
AEI
Alset
N/AN/AN/AN/AN/A
AWGI
Catapult Solutions
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alset Inc. stock logo
AEI
Alset
N/A
13.10
13.10
AWGI
Catapult Solutions
N/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.54
1.12

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alset Inc. stock logo
AEI
Alset
2.74%
AWGI
Catapult Solutions
N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Alset Inc. stock logo
AEI
Alset
53.52%
AWGI
Catapult Solutions
2.29%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
4.97%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alset Inc. stock logo
AEI
Alset
609.24 million4.29 millionNot Optionable
AWGI
Catapult Solutions
3N/AN/ANot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20873.05 million69.42 millionOptionable

PLX, TOX, AEI, 1AG, and AWGI Headlines

SourceHeadline
Protalix BioTherapeutics (NYSE:PLX) Trading Up 1.7%Protalix BioTherapeutics (NYSE:PLX) Trading Up 1.7%
americanbankingnews.com - April 24 at 3:00 AM
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 16 at 2:19 PM
Earnings call: Protalix BioTherapeutics reports fiscal year 2023 resultsEarnings call: Protalix BioTherapeutics reports fiscal year 2023 results
uk.investing.com - March 16 at 2:19 PM
Production cuts, geopolitical tensions drive oil rallyProduction cuts, geopolitical tensions drive oil rally
ca.finance.yahoo.com - March 15 at 3:47 PM
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 15 at 1:25 PM
PLX: Elfabrio Geographic ExpansionPLX: Elfabrio Geographic Expansion
finance.yahoo.com - March 15 at 10:47 AM
Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
finanznachrichten.de - March 14 at 8:43 AM
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
finance.yahoo.com - March 14 at 8:43 AM
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
prnewswire.com - March 14 at 6:50 AM
Heres what Wall Street expects from Protalix BioTherapeuticss earnings reportHere's what Wall Street expects from Protalix BioTherapeutics's earnings report
markets.businessinsider.com - March 13 at 5:33 PM
Earnings Preview: Protalix BioTherapeuticsEarnings Preview: Protalix BioTherapeutics
benzinga.com - March 13 at 5:33 PM
Protalix Biotherapeutics, Inc.Protalix Biotherapeutics, Inc.
edition.cnn.com - March 9 at 1:28 PM
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
finance.yahoo.com - March 7 at 8:30 AM
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor ConferenceProtalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
prnewswire.com - February 23 at 6:50 AM
PLX Mar 2024 1.500 callPLX Mar 2024 1.500 call
ca.finance.yahoo.com - February 17 at 1:05 AM
Abeona issues update on FDA market application for pz-celAbeona issues update on FDA market application for pz-cel
msn.com - February 2 at 7:17 AM
Will These 3 Biotech Stocks Make Gains in 2024?Will These 3 Biotech Stocks Make Gains in 2024?
entrepreneur.com - January 25 at 7:43 AM
Protalix BioTherapeutics Inc. [PLX] Investment Appeal on the RiseProtalix BioTherapeutics Inc. [PLX] Investment Appeal on the Rise
knoxdaily.com - January 2 at 6:59 PM
Protalix BioTherapeutics Issues 2024 Letter to StockholdersProtalix BioTherapeutics Issues 2024 Letter to Stockholders
finance.yahoo.com - December 26 at 7:21 AM
Protalix BioTherapeutics Stock (AMEX:PLX) Insider TradesProtalix BioTherapeutics Stock (AMEX:PLX) Insider Trades
benzinga.com - December 15 at 11:33 PM
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a BuyH.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy
knoxdaily.com - November 13 at 3:59 PM
PLX: More Regulatory ApprovalsPLX: More Regulatory Approvals
finance.yahoo.com - November 7 at 9:39 AM
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 7 at 9:39 AM
American Well, Protalix BioTherapeutics among healthcare moversAmerican Well, Protalix BioTherapeutics among healthcare movers
msn.com - November 6 at 10:40 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alset logo

Alset

NASDAQ:AEI
Alset Inc., together with its subsidiaries, engages in the real estate development, financial services, digital transformation technologies, biohealth activities, and consumer products businesses in the United States, Singapore, Hong Kong, Australia, and South Korea. It operates through four segments: Real Estate, Digital Transformation Technology, Biohealth, and Other Business Activities segments. The Real Estate segment develops property projects and participates in third-party property development projects; and owns, operates, and manages real estate development projects with a focus on land subdivision developments and house rental projects. The Digital Transformation Technology segment provides consulting, implementation, and development services with various technologies, including blockchain, e-commerce, social media, and payment solutions. Its technology platform focuses on business-to-business solutions, such as communications and workflow, instant messaging, international calling, social media, e-commerce and payment systems, and direct marketing solutions. The Biohealth segment engages in developing, researching, testing, manufacturing, licensing, and distributing biohealth products and services. The Other Business Activities segment offers corporate strategy and business development, asset management, corporate restructuring, and leveraged buy-out expertise services. It also operates cafes which is located in Singapore and South Korea. The company was formerly known as Alset EHome International Inc. and changed its name to Alset Inc. in October 2022. Alset Inc. was incorporated in 2018 and is headquartered in Bethesda, Maryland.

Catapult Solutions

OTCMKTS:AWGI
Ambient Water Corporation designs and builds air-to-water appliances for residential and commercial drinking water applications based on patented, patent pending, and proprietary technologies in the United States. The company's air-to-water technology systems produce water from the atmosphere by using a condensing surface and a proprietary filtration system that removes dust, airborne particles, and bacteria to generate drinking water. It serves businesses, governments, and individuals. The company was formerly known as AWG International Water Corporation and changed its name to Ambient Water Corporation in June 2014. Ambient Water Corporation was founded in 2010 and is headquartered in Spokane Valley, Washington.
Protalix BioTherapeutics logo

Protalix BioTherapeutics

NYSE:PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.